This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novartis Gets Approval for Remicade Biosimilar in Europe
by Zacks Equity Research
Novartis' (NVS) Sandoz wins approval for a biosimilar version of Remicade in Europe, which should further strengthen its biosimilars portfolio.
bluebird's Lenti-D Gets Breakthrough Therapy Status From FDA
by Zacks Equity Research
bluebird (BLUE) obtained Breakthrough Therapy designation from the FDA for Lenti-D for the treatment of patients with cerebral adrenoleukodystrophy, which should expedite its development.
Is Genome Editing the Next Biotech Breakthrough?
by David Borun
CRISPR technology is promising to be the foundation the treatment of 1000s of diseases
Eli Lilly Gets FDA Approval for Taltz in Genital Psoriasis
by Zacks Equity Research
Eli Lilly (LLY) gets FDA approval for label expansion of its psoriasis injection Taltz to include data for psoriasis involving the genital area.
Should You Hold Momenta (MNTA) Stock in Your Portfolio?
by Zacks Equity Research
Momenta (MNTA) is conducting a strategic review of its ongoing operations as revenues from Glatopa continue to decline.
Roche (RHHBY) Announces Positive Data on Hemophilia Drug
by Zacks Equity Research
Roche (RHHBY) announces positive data from two phase III studies on hemophilia drug Hemlibra which has further strengthened its hemophilia portfolio.
Migraine Space in Focus as AMGN/NVS' Aimovig Gets FDA Nod
by Zacks Equity Research
Migraine is one of the top 10 causes of years lived with disability globally. With Aimovig receiving FDA approval for treatment of migraine, investors' attention is on future regulatory decisions.
Amgen's Migraine Drug Aimovig Gets FDA Approval, Shares Up
by Zacks Equity Research
Amgen's (AMGN) preventive treatment for migraine, Aimovig, gets approval in the United States.
Pfizer Gets FDA Nod for Amgen, J&J's Anemia Drug Biosimilar
by Zacks Equity Research
Pfizer's (PFE) Retacrit, a biosimilar of Amgen's Epogen and J&J's Procrit gets FDA approval. The drug will be available for the treatment of anemia.
Eli Lilly's Cluster Headache Candidate Succeeds in Phase III
by Zacks Equity Research
Eli Lilly's (LLY) galcanezumab meets the primary endpoint in a late-stage study evaluating it for the prevention of episodic cluster headache.
Teva Stock Up 5% as Buffett's Berkshire Raises Stake in Q1
by Zacks Equity Research
Teva's (TEVA) shares gain 5% after Warren Buffett's Berkshire Hathaway reveals an increased stake in the company.
Novartis Multiple Sclerosis Drug Gets FDA Nod for Adolescents
by Zacks Equity Research
The FDA approves Novartis' (NVS) multiple sclerosis drug Gilenya for the treatment of children and adolescents aged between 10 and 18.
Ligand (LGND) Beats on Q1 Earnings & Revenues, Keeps View
by Zacks Equity Research
Ligand (LGND) beats both earnings and sales estimates in the first quarter of 2018. The company repeats its previous guidance for 2018.
Aerie (AERI) Incurs Lower Loss in Q1, Launches Rhopressa
by Zacks Equity Research
Aerie (AERI) reported a narrower-than-expected loss in the first quarter. The launch of the lead drug Rhopressa is underway.
Intercept (ICPT) Q1 Loss Narrower Than Expected, Sales Lag
by Zacks Equity Research
Intercept's (ICPT) first-quarter results were mixed as loss was narrower than expectations but sales missed expectations. The company also provided Ocaliva sales guidance for 2018.
Teva (TEVA) Stock Dips Despite Q1 Earnings & Sales Beat
by Zacks Equity Research
Teva's (TEVA) shares dip despite first-quarter earnings and sales beat. The company raises its 2018 sales and earnings outlook.
Pharma Stock Roundup: Mixed Q1 for MRK, PFE, FDA Nod for Kymriah's 2nd Indication
by Zacks Equity Research
Earnings are in focus this week with Pfizer (PFE) and Merck (MRK) delivering mixed Q1 numbers. Novartis gains FDA approval for the second indication of its CAR-T therapy, Kymriah.
Aduro (ADRO) Q1 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Aduro's (ADRO) loss in Q1 narrows from the estimate. Moreover, revenues top the same and surge substantially year over year on receipt of a milestone payment.
Conatus' (CNAT) Q1 Loss In Line, Revenues Beat Estimates
by Zacks Equity Research
Conatus (CNAT) reports in-line loss in Q1 while revenues beat estimates. Moreover, the top line improves year over year.
What Lies Ahead for Ligand (LGND) This Earnings Season? (Revised)
by Zacks Equity Research
Ligand's (LGND) Captisol formulation technology propels the company to pair up with several leading healthcare companies, which in turn might drive the stock in Q1.
What Lies Ahead for Ligand (LGND) This Earnings Season?
by Zacks Equity Research
Ligand's (LGND) Captisol formulation technology propels the company to pair up with several leading healthcare companies, which in turn might drive the stock in Q1.
Incyte (INCY) Incurs Loss in Q1, Revenues Miss Estimates
by Zacks Equity Research
Incyte (INCY) reported disappointing results for the first quarter wherein the company reported a loss against expectation of earnings and sales too missed estimates.
Roche (RHHBY) Q1 Earnings: Ocrevus, Perjeta Drive Sales Beat
by Zacks Equity Research
Roche (RHHBY) beat sales estimates in the first quarter driven by strong performance of Ocrevus and Perjeta which offset the legacy sales decline.
What's in the Cards for Conatus (CNAT) This Earnings Season?
by Zacks Equity Research
Conatus' (CNAT) might see improvement in Q1 courtesy of its lead candidate emricasan. However, the company's portfolio is devoid of an approved product and its resulting revenues.
Can Jafaki Help Incyte (INCY) Beat Earnings Estimates in Q1?
by Zacks Equity Research
Incyte (INCY) is likely to beat on earnings when it reports first-quarter results on May 1 driven by strong Jakafi sales.